GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocuphire Pharma Inc (NAS:OCUP) » Definitions » EPS (Diluted)

Ocuphire Pharma (Ocuphire Pharma) EPS (Diluted) : $-0.48 (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Ocuphire Pharma EPS (Diluted)?

Ocuphire Pharma's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.21. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.48.

Ocuphire Pharma's EPS (Basic) for the three months ended in Dec. 2023 was $-0.21. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.47.

Ocuphire Pharma's EPS without NRI for the three months ended in Dec. 2023 was $-0.21. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.48.

During the past 12 months, Ocuphire Pharma's average EPS without NRIGrowth Rate was -153.20% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 49.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Ocuphire Pharma's highest 3-Year average EPS without NRI Growth Rate was 49.00% per year. The lowest was 49.00% per year. And the median was 49.00% per year.


Ocuphire Pharma EPS (Diluted) Historical Data

The historical data trend for Ocuphire Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocuphire Pharma EPS (Diluted) Chart

Ocuphire Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-0.87 -5.28 -3.82 0.87 -0.46

Ocuphire Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.58 -0.28 -0.24 0.25 -0.21

Competitive Comparison of Ocuphire Pharma's EPS (Diluted)

For the Biotechnology subindustry, Ocuphire Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocuphire Pharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocuphire Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Ocuphire Pharma's PE Ratio falls into.



Ocuphire Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Ocuphire Pharma's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-9.986-0)/21.590
=-0.46

Ocuphire Pharma's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.795-0)/23.008
=-0.21

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocuphire Pharma  (NAS:OCUP) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ocuphire Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Ocuphire Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocuphire Pharma (Ocuphire Pharma) Business Description

Traded in Other Exchanges
Address
37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Executives
George Magrath officer: Chief Executive Officer 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel officer: SVP, Operations & Bus. Dev. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch director, officer: President and CEO 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J director 5130 ROUTE 212, WILLOW NY 12495
Jay Pepose director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton director 3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba officer: VP of Finance 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer director
Sean Ainsworth director 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann officer: VP of Corp. Dev. & Ops & Sec. 37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price director 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky officer: President and CFO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan officer: Chief Business Officer 36 ROCKLAND MILLS, ROCKLAND DE 19732